The purpose of this study is to determine if Cyrcadia's Circadian Biometric Recorder
(CBR™), which is attached to soft biometric patches worn on the body, can improve early
breast cancer detection along with mammography or as a stand alone device.
Additional locations may be listed on ClinicalTrials.gov for NCT02511301.
See trial information on ClinicalTrials.gov for a list of participating sites.
The Cyrcadia CBR™ (Circadian Biometric Recorder) includes wearable biometric patches and
a detachable data recording device. The CBR™ records chronobiologic data while the
patient is totally ambulatory and going about her normal daily routine. Following removal
of the detachable data recording device from the wearable biometric patches, the data is
transferred to a computer for analysis. The Cyrcadia CBR™ will be placed on the patient
for the duration of 2 to 24 hours. There is no restriction of daily activity. The study
subject is requested to sponge bathe rather than shower while wearing the device, keeping
the device dry during the testing procedure. After this period, the CBR™ will be removed
and the data will be transferred to a computer for analysis.
The primary endpoint of this 173 patient study is to determine the accuracy of Cyrcadia
CBR™ as a supplemental screening device to mammography and ultrasound in predicting a
diagnosis of breast cancer. Specific emphasis will be on the utilization of the CBR as a
secondary screening device to reduce the number of biopsies currently performed on
non-cancerous tissue. A secondary emphasis will be on the CBR to act as an improved
screening solution over mammography specifically in those patients with dense breast
parenchymal tissue.
Other endpoints of the study are:
- to determine the accuracy of Cyrcadia CBR™, including the positive predictive value,
negative predictive value, false negative rate and false positive rate.
- to determine the optimal wear time for the Cyrcadia CBR™.
- to demonstrate substantial equivalent or improved results when applied to Cyrcadia
original patient case study with identical advanced neural network analysis
computational results.
Study subjects will be followed at 6, 12, 18, and 24 months to update their clinical
status.
Lead OrganizationCyrcadia Health